Gly-ACV | 84499-62-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Gly-ACV
• 英文别名: Glycine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester；2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl 2-aminoacetate
• CAS: 84499-62-7
• 化学式: C₁₀H₁₄N₆O₄
• 分子量: 282.259
• InChiKey: LOOICXPOOTTXRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  147
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  鸟嘌呤 在 palladium on activated charcoal 4-二甲氨基吡啶 、 三氟甲磺酸 、 氢气 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 70.0h， 生成 Gly-ACV
  参考文献：
  名称：

  阿昔洛韦及其各种前药的区域选择性合成

  摘要：

  9-[(2-羟基乙氧基) 甲基] 鸟嘌呤（阿昔洛韦1，方案1）的高产区域选择性合成是从鸟嘌呤通过三甲硅烷基化鸟嘌呤实现的。N 2-acylacyclovir 9a-9b 由 N 2, O-diacylacyclovir (4, 8b-8d) 使用区域选择性脱酰程序制备。N 2-无环鸟苷11和13通过伯羟基的保护制备。阿昔洛韦的三种氨基酸酯合成为水溶性前药，在 pH 7.4 磷酸盐缓冲液中形成质子化阳离子。还合成了两种具有游离羧酸的水溶性酯前药，它们在 pH 7.4 的磷酸盐缓冲液中形成阴离子物质。方案 1. 试剂和条件： i．乙酸酐，HOAc，DMAP，160°C，8小时，3：88%；ii. P-TsOH、1,3-二氧戊环、Ac2O、HOAc；然后，甲苯，回流，1小时，4：18%；5：2.3%；4和5：52%；三、40% CH3NH2水溶液，1:93%。

  DOI：

  10.1081/scc-100104050

文献信息

• Topical iontophoretic delivery of ionizable, biolabile aciclovir prodrugs: A rational approach to improve cutaneous bioavailability
  作者：Yong Chen、Ingo Alberti、Yogeshvar N. Kalia

  DOI：10.1016/j.ejpb.2015.12.002

  日期：2016.2

  The objective was to investigate the topical iontophoretic delivery of a series of amino acid ester prodrugs of aciclovir (ACV-X, where ACV = aciclovir and X = Arg, Gly, Ile, Phe, Trp and Val) as a means to enhance cutaneous delivery of ACV. The newly synthesized prodrugs were characterized by H-1 NMR and high resolution mass spectrometry. Analytical methods using HPLC-UV were developed for their quantification and each method was validated. Investigation of solution stability as a function of pH showed that all ACV-X prodrugs were relatively stable in acid conditions at pH 2.0 and pH 5.5 for up to 8 h but susceptible to extensive hydrolysis at pH 7.4 and under alkaline conditions (pH 10). No ACV-X hydrolysis was observed after contact for 2 h with the external surface of porcine stratum corneum. However, there was significant hydrolysis following contact with the dermal surface of dermatomed porcine skin, in particular, for ACV-Arg. Passive transport of ACV and ACV-X prodrugs from aqueous solution after 2 h was below the limit of detection. Iontophoresis of ACV at 0.5 mA/cm(2) for 2 h led to modest ACV skin deposition (Q(DEP,ACV)) of 4.6 +/- 0.3 nmol/cm(2). In contrast, iontophoresis of ACV-X prodrugs under the same conditions produced order of magnitude increases in cutaneous deposition of ACV species, that is, Q(DEP,TOTAL) = Q(DEP,ACV) + Q(DEP,ACV-X). Q(DEP,TOTAL) for ACV-Gly, ACV-Val, ACV-Ile, ACV-Phe, ACV-Trp and ACV-Arg was 412.8 +/- 44.0, 358.8 +/- 66.8, 434.1 +/- 68.2, 249.8 +/- 81.4, 156.1 +/- 76.3, 785.9 +/- 78.1 nmol/cm(2), respectively. The extent of bioconversion of ACV -X to ACV in the skin was high and the proportion of ACV present ranged from 81% to 100%. The skin retention ratio, a measure of the selectivity of ACV species for deposition over permeation after iontophoretic delivery of ACV -X prodrugs, was dependent on both the rate of transport and the susceptibility to hydrolysis of the prodrugs. Skin deposition of ACV and its six prodrugs were investigated further as a function of current density (0.125, 0.25 and 0.5 mA/cm(2)); the effect of duration of current application (5,10, 30, 60 and 120 min) was evaluated using ACV-Arg and ACV-Ile. Iontophoresis of ACV-Arg and ACV-Ile at 0.25 mA/cm(2) for only 5 min resulted in the deposition of appreciable amounts of ACV (36.4 +/- 5.7 nmol/cm(2) and 40.3 +/- 6.1 nmol/cm(2), respectively), corresponding to supra-therapeutic average concentrations in skin against HSV-1 or HSV-2. The results demonstrated that cutaneous bioavailability of ACV could be significantly improved after short duration iontophoresis of ionizable, biolabile ACV -X prodrugs. (C) 2015 Elsevier B.V. All rights reserved.
• REGIOSELECTIVE SYNTHESIS OF ACYCLOVIR AND ITS VARIOUS PRODRUGS
  作者：Hongwu Gao、Ashim K. Mitra

  DOI：10.1081/scc-100104050

  日期：2001.1

  High-yield regioselective synthesis of 9-[(2-hydroxyethoxy) methyl]guanine (Acyclovir 1, Scheme 1) was achieved from guanine via trisilylated guanine. N 2-acylacyclovir 9a–9b were prepared from N 2, O-diacylacyclovir (4, 8b–8d) using regioselective deacylation procedure. N 2- Acylacyclovir 11 and 13 were prepared via protection of primary hydroxyl groups. Three amino acid esters of acyclovir were synthesized

  9-[(2-羟基乙氧基) 甲基] 鸟嘌呤（阿昔洛韦1，方案1）的高产区域选择性合成是从鸟嘌呤通过三甲硅烷基化鸟嘌呤实现的。N 2-acylacyclovir 9a-9b 由 N 2, O-diacylacyclovir (4, 8b-8d) 使用区域选择性脱酰程序制备。N 2-无环鸟苷11和13通过伯羟基的保护制备。阿昔洛韦的三种氨基酸酯合成为水溶性前药，在 pH 7.4 磷酸盐缓冲液中形成质子化阳离子。还合成了两种具有游离羧酸的水溶性酯前药，它们在 pH 7.4 的磷酸盐缓冲液中形成阴离子物质。方案 1. 试剂和条件： i．乙酸酐，HOAc，DMAP，160°C，8小时，3：88%；ii. P-TsOH、1,3-二氧戊环、Ac2O、HOAc；然后，甲苯，回流，1小时，4：18%；5：2.3%；4和5：52%；三、40% CH3NH2水溶液，1:93%。